FDA warns Dr. Ignacio J. Rodriguez for enrolling ineligible subjects and giving study drug without required checks in a clinical trial.
What happened
FDA inspected Dr. Rodriguez's clinical site between August 18 and September 29, 2020, and reviewed records and his October 20, 2020 response. FDA found that he enrolled and randomized subjects who met exclusion criteria, randomized subjects without required randomization criteria, and gave study drug without required assessments or central reviewer confirmation. FDA said these failures jeopardized subject safety and the validity of the data.
What FDA found
Failed to ensure the clinical investigation was conducted according to the investigational plan.
21 CFR 312.60Enrolled and randomized subjects who had conditions that the protocol required be excluded.
21 CFR 312.60Randomized subjects without meeting required randomization criteria, including required prior tests and calls into the study's randomization system.
21 CFR 312.60Administered study drug without required assessments or before the central reviewer confirmed eligibility.
21 CFR 312.60
What FDA wants
Within 15 days of receiving the letter, notify FDA in writing of actions taken to prevent similar violations. If you believe you complied, include your reasoning and supporting information.
Who should pay attention
- sponsors and CROs relying on clinical site data
- other clinical investigators and site staff
- IRBs overseeing drug trials
This is a summary. Read the original letter on fda.gov.